Unigene Laboratories  and Tarix Pharmaceuticals have entered into a definitive licensing agreement to develop an oral formulation of Tarix’s lead peptide drug candidate TXA127, using Unigene’s Peptelligence technology platform.   Tarix will have an exclusive worldwide license to Unigene’s Peptelligence technology for use with Angiotensin (1-7), the pharmaceutical ingredient in TXA127, as well as its functional equivalents, analogs or derivatives. Unigene will receive a percenta...